Small Animal Imaging Global Market Report 2023 – By Component (Micro MRI, Optical Imaging, Nuclear Imaging, Other Components), By Application (Monitoring Treatment Response, Bio Distribution, Determining Drug or Target Engagement, Cancer Cell Detection, Biomarkers, Longitudinal Studies, Epigenetics), By End User (Veterinary Clinics, Veterinary Hospitals, Veterinary Institutes and Research Centers) – Market Size, Trends, And Global Forecast 2023-2032 

Animal growth promoters and performance enhancers refer to the substances that are added to feeds as supplements or injections to increase feed utilization and growth in farm animals, as well as veterinary medicinal products that are administered to healthy animals in order to favourably influence the yield, quality, and/or growth of animal products. The main types of animal growth promoters and performance enhancers are antibiotic growth promoters and non-antibiotic growth promoters. Antibiotic growth promoters refer to the promoters that will enhance the health of the animal and increase productivity. These include natural chemicals such as microbial products, prebiotics, and probiotics, yeast products, enzymes and herbs, oils, and spices. The different types of animals that use animal growth promoters and performance enhancers include poultry, swine, livestock, aquaculture, and other animals. The global animal growth promoters and performance enhancers market is segmented – 1) By Type: Antibiotic Growth Promoters, Non-Antibiotic Growth Promoters 2) By Animal Type: Poultry, Swine, Livestock, Aquaculture, Other Animals 3) By Nature of Chemicals: Microbial Products, Prebiotics And Probiotics, Yeast Products, Enzymes/Herbs, Oils And Spices The global animal growth promoters and performance enhancers market size will grow from $13.73 billion in 2022 to $14.65 billion in 2023 at a compound annual growth rate (CAGR) of 6.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global animal growth promoters and performance enhancers market size is expected to grow to $18.92 billion in 2027 at a CAGR of 6.6%. The growing demand for meat is a significant factor that will drive the market for animal growth promoters and performance enhancers. Animal growth promoters make the animal accumulate fat and weight, resulting in more meat production and a more expensive animal. Meat is a major protein source for many people around the world. According to a study by FAO, the production of meat has doubled in the last 30 years and increased four-fold since the mid-1960s. The production and consumption of meat are expected to continue to grow. By 2050, global meat consumption is projected to reach between 460 million and 570 million tons. This is expected to drive the animal growth promoters and performance enhancers market. Major players in the animal growth promoters and performance enhancers market are Merck Animal Health, Cargill, Royal DSM N.V., Vetoquinol S.A., Bupo Animal Health, Elanco Animal Health Inc., Alltech, Bayer Animal Health, Zoetis, and Bioniche Life Sciences. Strict rules set by the US and European governments on the use of animal growth promoters and performance enhancers are restricting the animal growth promoter and performance enhancers market. For instance, Zoetis, the largest producer of animal medicines, is banned from selling antibiotics that promote faster growth in animals in the US and Europe. The US FDA has implemented a regulation that bans the use of antibiotics as feed supplements to help livestock and poultry grow faster. These regulations are expected to negatively impact the growth of the animal growth promoters and performance enhancers market. Companies in the market are increasingly investing in phytogenics for higher efficiency of growth promoters through natural means. Phytogenics, sometimes also referred to as botanicals or phytobiotics, are plant-based feed additives utilised in animal nutrition. They are derived from herbs, spices, and extracts. Phytochemicals can be used in solid, dried, and ground form or as extracts, and can also be classified as essential oils and oleoresins depending on the process used to derive the active ingredients. The use of phytogenics promotes increased feed intake, improved gut function, prevention of diarrhea, and antimicrobial and antioxidative effects in livestock. Companies such as Delacon, Cargill, and BIOMIN have invested in phytogenics. In June 2020, Elanco acquired Bayer Animal Health for $7.6 billion. This acquisition is expected to help Elanco expand its product profile and reach for medicines for pets and livestock. Bayer Animal Health is a division of Bayer HealthCare. North America was the largest region in the animal growth promoters and performance enhancers market in 2022. Asia-Pacific was the second-largest region in the global animal growth promoters and performance enhancers market. The regions covered in the global animal growth promoters and performance enhancers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the animal growth promoters and performance enhancers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The animal growth promoters and performance enhancers market consists of sales of growth hormone medications, anabolic implants, bovine somatotropin, ß-agonists and probiotics. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The animal growth promoters and performance enhancers report is one of a series of new reports from The Business Research Company that provides animal growth promoters and performance enhancers market statistics, including animal growth promoters and performance enhancers industry global market size, regional shares, competitors with animal growth promoters and performance enhancers market share, detailed animal growth promoters and performance enhancers market segments, market trends and opportunities, and any further data you may need to thrive in the animal growth promoters and performance enhancers industry. This animal growth promoters and performance enhancers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Animal medicines refer to a collective term for drugs and therapies, including veterinary vaccines, veterinary antibiotics, and other veterinary pharmaceuticals, that are used to treat animal diseases to improve animals’ performance and health by identifying disease symptoms and drugs for the cure of illness. The main types of animal medicines are veterinary pharmaceuticals and feed additives, which are used for livestock and companion animals. Veterinary pharmaceuticals refer to animal medicine that is given to animals for treating diseases. Animal medicine is used by veterinary hospitals, pharmacies, drug stores, and veterinary clinics. The global animal medicine market is segmented - 1) By Type: Veterinary Pharmaceuticals, Feed Additives 2) By Type of Animal: Livestock, Companion Animals 3) By End-Use: Veterinary Hospitals, Pharmacies And Drug Stores, Veterinary Clinics Subsegments Covered: Veterinary Vaccines, Veterinary Antibiotics, Veterinary Parasiticides, Other Veterinary Pharmaceuticals, Medical Feed Additives, Nutritional Feed Additives The global animal medicine market size will grow from $46.91 billion in 2022 to $50.47 billion in 2023 at a compound annual growth rate (CAGR) of 7.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, and affecting many markets across the globe. The market size of animal medicine is expected to grow from $65.12 billion in 2027 at a CAGR of 6.6%. The increasing penetration of pet insurance is expected to drive the animal medicine market. Globally, the pet insurance market is largely untapped with extremely low penetration rates, providing a large market opportunity. In developed economies such as the USA, the pet insurance penetration rate is around 1%, although in Western European countries such as the UK, the penetration rate is around 20%. During the forecast period, the pet insurance market in the USA is expected to grow by $2 billion in 2022, at a compound annual growth rate of 14%, mainly driven by the increasing consumer awareness and rising disposable income of companion animal owners. Increasing penetration of pet insurance will increase the number of visits at veterinary clinics supporting the use of animal medicine in the treatment of different diseases. Major companies in the animal medicine market include Zoetis Inc., Boehringer Ingelheim GmbH, Merck & Co, Evonik Industries AG, Patterson Companies Inc., Ceva Animal Health LLC – Biomune, Phirbo Animal Health, Dechra Pharmaceuticals, Virbac Group, and Vetoquinol S.A. The outbreak of COVID-19 disease (COVID-19) has acted as a massive restraint on the animal medicine market in 2020 as supply chains were disrupted due to trade restrictions and consumption declined due to lockdowns imposed by governments globally. COVID-19 is an infectious disease with flu-like symptoms including fever, cough, and difficulty breathing. The virus was first identified in 2019 in Wuhan, Hubei province of the People’s Republic of China, and has spread globally, including Western Europe, North America, and Asia. Steps by national governments to contain the transmission have resulted in a decline in economic activity with countries entering a state of "lock down" and the outbreak hurting businesses throughout 2020 and into 2021. However, it is expected that the animal medicine market will recover from the shock over the forecast period as it is a "black swan" event and not related to ongoing or fundamental weaknesses in the market or the global economy. Nanotechnology is increasingly gaining traction in the animal medicine market as a substitute for veterinary antibiotics. Nanotechnology is the study of controlling matter on an atomic and molecular scale. In the animal medicine industry, nanotechnology is used to improve diagnosis, treatment, animal growth promotion, and production. Nanoparticles are mainly used as alternative antimicrobial agents to reduce the use of antibiotics and improve the detection of pathogenic bacteria. They are also used as drug delivery agents for new drugs and vaccine candidates to improve their characteristics and performance and to reduce drug resistance in animal organisms. North America was the largest region in animal medicine market in 2022. Asia-Pacific was the second-largest region in the animal medicine market analysis. The regions covered in the animal medicine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the animal medicine market include Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The animal medicine market consists of sales of procuring drugs to shield against external parasites like fleas, ticks, and heartworms (intestinal parasites). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The animal medicine research report is one of a series of new reports from The Business Research Company that provides animal medicine statistics, including animal medicine industry global market size, regional shares, competitors with animal medicine shares, detailed animal medicine segments, market trends and opportunities, and any further data you may need to thrive in the animal medicine industry. This animal medicine research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Animal hospitals and veterinary clinics refer to a type of premises at which veterinary surgery is practiced but at which animals are not retained overnight, whereas in veterinary hospitals, veterinary surgery is practiced and animals receive treatment and nursing care, and other services include the reception, treatment, and care of animals suffering from disease or injury or in need of surgical or medical treatment or assistance. The main types of animal hospitals and veterinary clinics' services are consultation, surgery, medicine, and other types. Veterinary doctors perform the surgery to correct any medical issues that animals may have. The types of animals that avail themselves of these services include farm animals and companion animals that are used in animal care, animal rescue, and other end-users. The global animal hospitals and veterinary clinics market is segmented - 1) By Type: Consultation, Surgery, Medicine, Other Types 2) By Animal Type: Farm Animals, Companion Animals 3) By End User: Animal Care, Animal Rescue, Other End Users The global animal hospitals and veterinary clinics market size grew from $107.76 billion in 2022 to $117.13 billion in 2023 at a compound annual growth rate (CAGR) of 8.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global animal hospitals and veterinary clinics is expected to grow to $157.02 billion in 2027 at a CAGR of 7.6%. The rise in the adoption of companion pets globally is driving the animal hospitals and veterinary clinics market demand. The key factor behind this rise in adoption is the increasing humanization of pets, as an increasing number of pet owners are accepting pets as family members. According to the American Veterinary Medical Association report, there was a correlation between the degree of human-animal bond and pet spending. According to the American Society for the Prevention of Cruelty to Animals (ASPCA), in the USA, approximately 3.2 million shelter animals are adopted each year. Also, according to a study, Americans spent about $17 billion on veterinary care in hospitals, clinics, and food. Similarly, Chinese pet owners spent more than 5,000 yuan per pet. With this growth, the animal hospitals and veterinary clinics market is expected to grow in the forecast period. Major players in the animal hospitals and veterinary clinics market are VCA Inc., Banfield Pet Hospital, Greencross Ltd., CVS Group PLC., Mars, Inc., National Veterinary Care Ltd., Pets at Home Group PLC., Ethos Veterinary Health, Animart LLC., and The Bargh Memorial Animal Hospital ASPCA. Veterinary healthcare access is relatively poor in most developing countries and some developed nations. Globally, the disease burden is significantly high in low and middle-income countries. For instance, India reported approximately 63,000 veterinarians while the country required more than 150,000 veterinarians. Thus, the shortage of skilled veterinary professionals is harming the growth of the animal hospital and veterinary clinic market. Many veterinary care service providers are adopting big data technologies to provide better treatment for pets, livestock, and animals. This technology is used to diagnose and assess potential diseases. Big data enables veterinarians to identify the diseases affecting cattle and pets in various locations and regions. For instance, Bayer Healthcare Animal introduced applications to assess potential signs of diseases in animals, thus enabling faster diagnosis and treatment of disease conditions. Some of the major veterinary care providers opting for big data analytics to treat pet health issues are VCA Inc., Banfield Pet Hospitals, and Greencross Limited. The animal hospital and veterinary clinic market is regulated by authorities such as the Australian Pesticides and Veterinary Medicines Authority (APVMA). In Australia, Section 24A of the Veterinary Surgeons Act 1960, prescribes that premises that will be or are used as a veterinary clinic or veterinary hospital (veterinary premises) must be registered by the Veterinary Surgeons’ Board (Board). The Board only registers veterinary premises when it is satisfied that the premises are suitable for the purpose for which they are proposed to be used and the veterinary premises are under the management of a veterinary surgeon. North America was the largest region in the animal hospitals and veterinary clinics market in 2022. Asia-Pacific was the second-largest region in the global animal hospitals and veterinary clinics market share. The regions covered in the animal hospitals and veterinary clinics market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the animal hospitals and veterinary clinics market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The animal hospitals and veterinary clinics market includes revenues earned by entities by providing diagnosis, treatment, and care to patients and offering preventive healthcare schedules to improve the health condition of pets and other animals. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The animal hospitals and veterinary clinics research report is one of a series of new reports from The Business Research Company that provides animal hospitals and veterinary clinics market statistics, including animal hospitals and veterinary clinics industry global market size, regional shares, competitors with animal hospitals and veterinary clinics market shares, detailed animal hospitals and veterinary clinics market segments, market trends and opportunities, and any further data you may need to thrive in the animal hospitals and veterinary clinics industry. This animal hospitals and veterinary clinics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The animal antibiotics and antimicrobials refer to veterinary medications that work against bacteria or microorganisms by either killing bacteria/microorganisms or limiting their development and multiplication. These medications are used in animals to treat clinical diseases, to prevent or control common disease events, and enhance animal growth. The main types of animal antibiotics and antimicrobials include tetracyclines, penicillins, sulfonamides, macrolides, aminoglycosides, lincosamides, fluoroquinolones, cephalosporins, and other antimicrobials and antibiotics. Tetracyclines are bacteriostatic, and their mechanism of action is through reversible binding of bacterial 30S ribosomes and alteration of bacterial cytoplasmic membrane. They are also referred to as oral medication used in treatment of bacterial infections due to aerobic, gram-negative bacteria, mycoplasma, and others. These are delivered in different forms including premixes, oral powder, oral solutions, injection, and others. These medications are used in both companion and food-producing animals. The global animal antibiotics and antimicrobials market is segmented – 1) By Type of Product: Tetracyclines, Penicillins, Sulfonamides, Macrolides, Aminoglycosides, Lincosamides, Fluoroquinolones, Cephalosporins, Other Antimicrobials and Antibiotics 2) By Mode of Delivery: Premixes, Oral Powder, Oral Solution, Injection, Other Modes of Delivery 3) By Animal Type: Food-Producing Animals, Companion Animals The global animal antibiotics and antimicrobials market size will grow from $4.68 billion in 2022 to $5.07 billion in 2023 at a compound annual growth rate (CAGR) of 8.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The size of animal antibiotics and antimicrobials market is expected to grow to $6.95 billion in 2027 at a CAGR of 8.2%. Rising demand for animal-derived food products is driving the growth of the animal antibiotics and antimicrobials market. Animal-derived food products such as milk, eggs, meat, and other act a major source of nutrition and plays a prominent role in human diet. The companies/institutions involved in production of animal-derived foods are focusing on developing healthy herd or disease-free herd through utilization of animal antibiotics and antimicrobials on precautionary basis. According to the data published in the Packaged Facts report on Global Meat & Poultry trends, global meat and poultry consumption is expected to reach 313 million metric tons in 2023, at a year-on-year growth rate of 1.4%. Therefore, increasing demand for animal-derived food products is expected to boost demand for animal antibiotics and antimicrobials during forecast period. Major players in the animal antibiotics and antimicrobials market are Boehringer Ingelheim, Zoetis Inc., Elanco Animal Health, Merck & Co. Inc., Phibro Animal Health, Vetoquinol SA, Lutim Pharma, Ceva Santé Animale, Dechra Pharmaceuticals PLC., Kyoritsu Seiyaku, Huvepharma Inc., Zydus, Indian Immunologicals Pvt. Ltd., Bayer Animal Health, Virbac Animal Health, and Phibro Animal Health Corp. Strategic partnership is a key trend gaining popularity in the animal antibiotics and antimicrobials market. The companies operating in animal antibiotics and antimicrobial sector are entering into strategic partnerships with relevant industry players for the research and development of innovative animal antibiotics and antimicrobials. In May 2022, Gnubiotics Sciences, a Switzerland-based biotech company working to solve microbiome-related health conditions in humans and animals, entered into a partnership with ADM, a US-based developer of human and health nutrition solutions, for commercializing new microbiome solutions for companion animal health and wellbeing. In August 2020, Elanco, a US-based pharmaceutical company that manufacturers medicines and vaccinations for pets and livestock, acquired Bayer’s animal health business unit for $6.89 billion. With this acquisition, Elanco will improve its research and development pipeline and broaden its range of animal health products. Bayer’s animal health business unit is a Germany-based pharmaceutical and life sciences company. North America was the largest region in the animal antibiotics and antimicrobials market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the animal antibiotics and antimicrobials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the animal antibiotics and antimicrobials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The animal antibiotics and antimicrobials market consists of sales of glycopeptides, ß-Lactam antibiotics, and polymixins. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The animal antibiotics and antimicrobials market research report is one of a series of new reports from The Business Research Company that provides animal antibiotics and antimicrobials market statistics, including animal antibiotics and antimicrobials industry global market size, regional shares, competitors with a animal antibiotics and antimicrobials market share, detailed animal antibiotics and antimicrobials market segments, market trends and opportunities, and any further data you may need to thrive in the animal antibiotics and antimicrobials industry. This animal antibiotics and antimicrobials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The animal-based protein supplements refer to dietary supplements that are used to complete the daily requirement of protein for the body and to enhance muscle synthesis and growth of lean muscle mass. Animal-based protein supplements are protein supplements extracted from animal sources, including eggs, milk, and collagen. Animal-based protein supplements are considered an excellent source of protein since they have all the essential amino acids and are considered a complete protein. They also have a more neutral taste and are blended easily. The main product types of animal-based protein supplements are supplements, protein powder, protein bars, ready-to-drink, and others. Protein powders are a convenient way of consuming protein and can be enriched with added enzymes, vitamins, and minerals to improve their nutritional value. The different raw materials include whey, casein, eggs, fish, and others that are used in pharmaceuticals and nutraceuticals, food and beverages, infant formulations, cosmetics and personal care, animal feed, and dietary supplements. It is distributed through several channels such as supermarkets and hypermarkets, online stores, chemists' or drugstores, specialty stores, and others. The global animal-based protein supplements market is segmented – 1) By Product: Protein Powder, Protein Bars, Ready-To-Drink, Other Products 2) By Raw Materials: Whey, Casein, Egg, Fish, Other Raw Materials 3) By Application: Pharmaceuticals and Nutraceuticals, Food and Beverages, Infant Formulations, Cosmetics and Personal Care, Animal Feed, And Dietary Supplements 4) By Distribution Channel: Supermarkets And Hypermarkets, Online Stores, Chemists or Drugstores, Specialty Stores, Other Distribution Channels The global animal-based protein supplements market size will grow from $25.59 billion in 2022 to $28.02 billion in 2023 at a compound annual growth rate (CAGR) of 9.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of animal based protein supplements is expected to grow to $40.07 billion in 2027 at a CAGR of 9.4%. The increasing number of health-conscious consumers is expected to drive the growth of the animal-based protein supplements market going forward. The number of people focusing on their health and nutrition has been increasing globally in recent years, due to which people are more aware of completing the daily protein requirement and its importance in bodily functions. To complete the protein requirement, people are moving towards animal-based protein supplements, which in turn are resulting in the growth of the demand for animal-based protein supplements. For instance, in March 2022, according to Avendus Capital, an India-based financial services firm, consumers who are concerned about their health are predicted to increase from 108 million in 2020 to 176 million in 2026. In addition, after the pandemic, 70% of Indians said they would prioritize dietary changes to improve their overall health. Therefore, the increasing number of health-conscious consumers is driving the demand for animal-based protein supplements. Major players in the animal-based protein supplements market are Glanbia plc, Abbott Laboratories, CytoSport Inc., MusclePharm Corporation, Iovate Health Sciences International Inc., AMCO Proteins, WOODBOLT DISTRIBUTION LLC, Quest Nutrition, NOW Foods, Transparent Labs, The Bountiful Company, Dymatize Enterprises LLC, BPI Sports LLC, JymSupplementScience, RSP Nutrition, and International Dehydrated Foods Inc., Product innovations have emerged as the key trend gaining popularity in the animal-based protein supplements market. Major companies operating in the animal-based protein supplements market are focused on developing new technological solutions to strengthen their position in the market. For instance, in 2021, GoodSport Nutrition, a US-based healthy sports drink manufacturing company, launched the GoodSport sports drink, a first-of-its-kind natural sports drink made from 97% dairy. The drink delivers three times more electrolytes and 33% less sugar than a conventional sports drink. According to the firm, research has shown that milk hydrates more effectively than other sports beverages and water. In February 2022, Nestlé Health Science, a Switzerland-based nutrition company, acquired Vital Proteins for an undisclosed amount. The acquisition would help Nestlé add another brand to its vitamin, mineral, supplement, and wellness portfolio. Vital Proteins is a US-based producer and marketer of animal collagen-based protein supplements. North America was the largest region in the animal-based protein supplements market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the animal-based protein supplements market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the animal-based protein supplements market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The animal-based protein supplements market consists of sales of egg white protein, collagen, and beef protein isolate. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The animal-based protein supplements market research report is one of a series of new reports from The Business Research Company that provides animal-based protein supplements market statistics, including global market size, regional shares, competitors with an animal-based protein supplements market share, detailed animal-based protein supplements market segments, market trends and opportunities, and any further data you may need to thrive in the animal-based protein supplements industry. This animal-based protein supplements market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Biophotonics is the combination of photonics and biology and is a multidisciplinary research field embracing all light-based technologies applied to life sciences and medicine. It is used to examine, control, and track biological processes at various levels of biology: cellular, tissue, molecular, and organism level. The biophotonics market consists of revenues generated from the sales of biophotonic instruments combining optics, nanotechnology, photonics, and biotechnology. Biophotonics is the combination of photonics and biology and is a multidisciplinary research field embracing all light-based technologies applied to life sciences and medicine. It refers to the use of photonic or optical means to examine, control, and track biological processes at various levels of biology: cellular, tissue, molecular, and organism level. The global biophotonics market is segmented - 1) By Product Technology: In-Vitro, In-Vivo 2) By Application: See-Through Imaging, Inside Imaging, Spectromolecular, Surface Imaging, Microscopy, Light Therapy, Biosensors, Other Applications 3) By End Use: Diagnostics, Therapeutic, Tests, Other End Uses The main product technologies in biophotonics are in-vitro and in-vivo. In vitro studies examine microorganisms, cells, and biological molecules outside of their natural biological framework. These studies in biology and its subdisciplines are generally done in labware such as test tubes, flasks, Petri dishes, and microtiter plates, and are referred to as test-tube investigations. The different applications include see-through imaging, inside imaging, spectromolecular, surface imaging, microscopy, light therapy, biosensors, and others and are used by various sectors such as diagnostics, therapeutic, tests, and others. The global biophotonics market size will grow from $67.04 billion in 2022 to $74.38 billion in 2023 at a compound annual growth rate (CAGR) of 10.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global biophotonics is expected to grow to $113.99 billion in 2027 at a CAGR of 11.3%. The increasing demand for minimally invasive surgeries is contributing to the growth of the biophotonics market. Optical engineering and imaging technologies are playing a vital role in the evolving field of minimally invasive surgeries by enabling to visualize the manipulation of tissue at remote internal sites. According to a report by Intuitive Surgical, Inc., a US-based company specializing in minimally invasive care and the pioneer of robotic-assisted surgery, stated that they performed 10 million surgeries in 2021. Therefore, the surge in the number of minimally invasive surgeries annually worldwide is generating higher revenues for the biophotonics market. Major players in the biophotonics market are Thermo Fisher Scientific, OPGEN, NU Skin Enterprises, IPG Photonics Corp., Idex Corp., Toshiba, Procter & Gamble, Horiba and Precision Photonics Corp. High prices of biophotonic-based devices or instruments are anticipated to limit the growth of the biophotonics market. The price of biophotonics is comparatively higher than that of conventional instruments. They are considered as more complex attributing to the integration of biological units and the generation, manipulation, and detection of light units, thereby rising their price. This will negatively impact the biophotonics market growth. The launch of new advanced techniques in the field of biotechnology is a major trend shaping the biophotonics market. For instance, a team of scientists at the University of St. Andrews (Scotland) developed a fluorescence microscopy technique that allows imaging of delicate biological samples with low damage in neuroscience and biomedicine. This low-damage optical technique is projected to transform the world of biomedicine in the forthcoming years. Hence, the development of new and advanced techniques is gaining significant popularity in the biophotonics market. In April 2021, CellaVision, a Sweden based company that offers digital Morphology Solutions acquired exclusive rights to a patent portfolio on Fourier Ptychographic Microscopy from Clearbridge BioPhotonics for $3.28 million (SEK 28.7 million). Through this acquisition, CellaVision will have access to and control over a promising future technology. CellaVision believes that the Fourier Ptychography Microscopy technology has the capability to be employed in the development of future automated microscopes for use in haematology and related fields. Clearbridge Biophotonics, Inc. is a US-based imaging solutions company. North America was the largest region in the biophotonics market in 2022. Western Europe was the second largest region in the global biophotonics market share. The regions covered in the global biophotonics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The biophotonics market includes revenue earned by systems, technologies, and instruments. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The biophotonics market research report is one of a series of new reports from The Business Research Company that provides biophotonics market statistics, including biophotonics industry global market size, regional shares, competitors with a biophotonics market share, detailed biophotonics market segments, market trends and opportunities, and any further data you may need to thrive in the biophotonics industry. This biophotonics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Chemicals are used in antimicrobial coatings to prevent pathogen growth by disrupting cellular membranes. In other words, an antimicrobial coating is a chemical substance that is applied to a surface to prevent disease-causing microorganisms from growing. These coatings not only improve the surface's durability, appearance, corrosion resistance, and so on, but they also protect it against disease-causing bacteria. The main types of antimicrobial medical device coatings are metallic coatings and non-metallic coatings. Metallic coatings contain a metallic element or alloy and are applied on devices or equipment for protection against corrosion, sunlight, and oxidation. Metallic coatings consist of silver coatings, copper coatings, and other metallic coatings. Non-metallic coatings can be added to metallic coatings to produce effective wear-resistant coatings. The different types of devices include catheters, implantable devices, surgical instruments, and others. It is implemented in areas such as orthopedics, general surgery, dentistry, cardiovascular, gynecology, and others and is used in hospitals, diagnostic centers, and ambulatory surgical centers. The global antimicrobial medical device coatings market is segmented - 1) By Type of Material: Metallic Coatings, Non Metallic Coatings 2) By Device Type: Catheters, Implantable Devices, Surgical Instruments, Other Device Types 3) By Application: Orthopedics, General Surgery, Dentistry, Cardiovascular, Gynecology, Other Applications 4) By End User: Hospitals, Diagnostic Centers, Ambulatory Surgical Centers The global antimicrobial medical device coatings market size grew from $2.1 billion in 2022 to $2.43 billion in 2023 at a compound annual growth rate (CAGR) of 16.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services, and affecting many markets across the globe. The antimicrobial medical device coatings market size is expected to grow to $4 billion in 2027 at a CAGR of 13.2%. The rising cardiovascular diseases drive the growth of the antimicrobial medical device coatings market over the coming years. CVDs (cardiovascular diseases) are a category of heart and blood vessel problems. Cardiovascular diseases (CVDs) are the primary, source of death worldwide with low- and middle-income nations accounting for three-quarters of CVD deaths. Antimicrobial coated cardiovascular devices are used for the treatment of cardiovascular diseases and disorders. According to the World Health Organization (WHO) report in 2021, cardiovascular diseases claimed the lives of 17.9 million individuals worldwide in 2019, accounting for 32% of all deaths. Heart attacks and strokes were responsible for 85% of these deaths. Major players in the antimicrobial medical device coatings market are AST Products Inc., BioInteractions Ltd., Covalon Technologies Ltd., Royal DSM, Hydromer, BASF SE, Sciessent LLC, DuPont de Nemours Inc., Kraton Corporation, Sono-Tek Corporation, and Microban International. The growing technological advancements are shaping the antimicrobial medical device coatings market. Major companies operating in the antimicrobial medical device coating sector are focused on developing technological solutions for antimicrobial medical device coatings to prevent the spread of viruses. For instance, in November 2020, Zonitise Ltd., a UK-based biotech firm, introduced an antimicrobial surface treatment based on nanotechnology that has been shown to destroy hazardous viruses and bacteria for up to twelve months after one application, including TGEV COVID-19, the model virus for SARS COV 2. This coating not only disinfects surfaces but also protects them in an antimicrobial sealant that destroys and prevents the formation of any hazardous bacteria that come into touch with it for up to twelve months. In February 2021, Bain Capital, a US-based investment firm, and Cinven, a UK-based private equity firm acquired Lonza Specialty Ingredients (LSI), a division of Lonza AG for $4.7 billion. Through this acquisition, LSI provides a range of differentiated specialty chemical products, underpinned by strong R&D capabilities, regulatory and IP protections, and a highly qualified and dedicated workforce. Lonza Specialty Ingredients (LSI) is a US-based company that specializes in microbial control for personal care as well as mold and other potential pathogen prevention in homes, schools, workplaces, and the environment. North America was the largest region in the antimicrobial medical device coatings market in 2022. Europe was the second-largest market in the antimicrobial medical device coatings market. The regions covered in the antimicrobial medical device coatings market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the antimicrobial medical device coatings market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The antimicrobial medical device coatings market consists of sales of non-metallic antimicrobial medical device coating including polymeric and organic coatings. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The antimicrobial medical device coatings market research report is one of a series of new reports from The Business Research Company that provides antimicrobial medical device coatings market statistics, including antimicrobial medical device coatings industry global market size, regional shares, competitors with an antimicrobial medical device coatings market share, detailed antimicrobial medical device coatings market segments, market trends and opportunities, and any further data you may need to thrive in the antimicrobial medical device coatings industry. This antimicrobial medical device coatings market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Veterinary orthopaedic implant is a surgical tool used to repair a broken bone structure and regain its function. Veterinary orthopaedic implants are typically made of metals such as pure commercial titanium (Ti) or titanium alloys, stainless steel, and cobalt-chromium (Co-Cr) alloys and are used by veterinary surgeons for bone fixation surgeries and treating bone fractures in animals.The orthopaedic implants are also used as a support structure for healing fractures and reconstructive surgeries. Orthopedic implants include screws, plates, pins, and wires, which are used in surgeries performed on animals. The main product types in veterinary orthopaedic implants are advanced locking plate systems, tibial plateau levelling osteotomy implants, tibial tuberosity advancement implants, total elbow replacement, total hip replacement, total knee replacement, and trauma fixations. A tibial plateau levelling osteotomy implants are used to repair cranial cruciate ligament ruptures in dogs. The veterinary orthopaedic implants are used for animals such as dogs and cats, as well as for end-users such as veterinary hospitals, clinics, and surgical centers. The global veterinary orthopedic implants market is segmented - 1) By Product Type: Advanced Locking Plate System, Tibial Plateau Leveling Osteotomy Implants, Tibial Tuberosity Advancement Implants, Total Elbow Replacement, Total Hip Replacement, Total Knee Replacement, Trauma Fixations 2) By Animal: Dog, Cat, Other Animals 3) By End-User: Veterinary Hospitals, Veterinary Clinics, Veterinary Surgical Centers The global veterinary orthopedic implants market size grew from $0.22 billion in 2022 to $0.24 billion in 2023 at a compound annual growth rate (CAGR) of 8.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the veterinary orthopedic implants is expected to grow from $0.32 billion in 2027 at a CAGR of 7.2%. Major players in the veterinary orthopaedic implants market are KYON Pharma Inc., Veterinary Orthopedic Implants Inc., BioMedtrix LLC., IMEX Veterinary Inc., Orthomed Ltd., Securos Surgical, B. Braun Vet Care, Bluesao, DePuy Synthes Vet, and MWI Veterinary Supply Co. The increase in the incidence of obesity and arthritis increases the demand for veterinary orthopaedic implants market. Obesity is a condition where the weight of the pet affects the pet's health to a point where it results in the weakening of bones, whereas arthritis in pets results in loss of strength in bones. Obesity and arthritis may also result in fractures, and other bone-joint-related issues and both conditions result in adversely affect the overall health of the pet, consequently leading to shortening lifespan. Thus, the increased incidents of obesity and arthritis increase the demand for veterinary orthopaedic implants. According to Banfield Pet Hospital’s report on 2.5 million dogs and 500,000 cats treated in the USA, the number of osteoarthritis (OA) cases increased 66% in dogs and 150% in cats. The report also inferred that 52% of dogs and 41% of cats with OA are also overweight or obese. Thus, the increase in health conditions affecting the bones of pets such as obesity and arthritis positively affect the veterinary orthopaedic market growth. The high cost of orthopaedic surgery inhibits the growth of the veterinary orthopaedic implants market. The surgery cost includes the equipment, X-ray, and consumables among others, which many of the households cannot afford. For instance, in the USA, a typical examination of the problem costs around $400 and the cost of orthopaedic surgery ranges from $1,500 to $4,000. Thus, the high cost of orthopaedic surgery restricts the growth of the veterinary orthopaedic market. The companies in the veterinary orthopaedic implants market are investing in 3D printing techniques for creating veterinary orthopaedic implants. 3D printing in the veterinary orthopaedics market is being used for creating printed bone models, surgical guides, and titanium implants. The use of 3D printing reduces the surgical time, and cost and removes the engineering complexities in orthopaedic procedures. Following the trend, many dogs with bone deformities have been treated by Langford Veterinary Services, a UK-based provider of veterinary services, through its collaboration with CBM. The collaboration enabled CBM to create 3D printed models of animal implants using titanium Ti6AI4V EL material. The MRI or CT scans are sent from Langford Veterinary Services in Bristol to CBM, then produces 3D printed models using Arcam EBM Q10plus machine. CBM is a U.K based company focused on advanced research, product development, and batch manufacturing facility. Thus, the use of 3D printing is one of the latest trends in the veterinary orthopaedic implants market and will contribute to the growth of the veterinary orthopaedic market. In August 2022, Vimian Group, a Sweden-based animal health company, acquired New Generation Devices’ assets. The acquisition, Vimian will get access to a new customer base, which they can tap to increase their revenues. New Generation Devices is a veterinary orthopaedic implant manufacturer based in the United States that was founded in 2002. North America was the largest region in the veterinary orthopaedic implants market in 2022. Western Europe was the second largest region in the global veterinary orthopaedic implants market share. The regions covered in the global veterinary orthopaedic implants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the veterinary orthopaedic implants are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The veterinary orthopedic implant market consists of sales screws, plates, pins, and wires. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The veterinary orthopaedic implants market research report is one of a series of new reports from The Business Research Company that provides veterinary orthopaedic implants market statistics, including veterinary orthopedic implants industry global market size, regional shares, competitors with a veterinary orthopaedic implants market share, detailed veterinary orthopaedic implants market segments, market trends and opportunities, and any further data you may need to thrive in the veterinary orthopaedic implants industry. The veterinary orthopaedic implants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.